Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

55.60
Delayed Data
As of 4:01pm ET
 +0.68 / +1.24%
Today’s Change
45.69
Today|||52-Week Range
61.70
+5.26%
Year-to-Date
Calpers seeks more access to Exxon's board
1:34pm / FT.com - Paid Partner Content
Why Endo International plc Investigated a Lower Price
May 11 / MotleyFool.com - Paid Partner Content
Pfizer Wants to Be Seen as an Oncology Powerhouse
11:49am / TheStreet.com - Paid Partner Content
Immune Design (IMDZ) Loss Narrower than Expected in Q1
May 11 / Zacks.com - Paid Partner Content
Will These Game-Changing Cancer Treatments Hit the Market in 2016?
May 19 / MotleyFool.com - Paid Partner Content
Do Sluggish Sales of Harvoni Make Gilead Sciences a "Sell"?
May 10 / MotleyFool.com - Paid Partner Content
European Markets Slump on Fed Rate-Rise Concern
May 19 / TheStreet.com - Paid Partner Content
1 Wonder Drug Sends Bristol-Myers Squibb Co. Rocketing 13% Higher in April
May 10 / MotleyFool.com - Paid Partner Content
Multibillion-dollar pharma levy proposed in superbugs battle
May 18 / FT.com - Paid Partner Content
Stock Market News for May 10, 2016
May 10 / Zacks.com - Paid Partner Content
This 10-Time Winner Is Offering A New Opportunity
May 18 / StreetAuthority - Paid Partner Content
Pfizer to trial triple-combination cancer treatment
May 09 / FT.com - Paid Partner Content
Biotech Is Showing Some Bargains
May 17 / TheStreet.com - Paid Partner Content
Vaccine development needs global alliance
Apr 24 / FT.com - Paid Partner Content
5 Surprising Comments in Merck's Quarterly Conference Call
May 13 / MotleyFool.com - Paid Partner Content
Vaccines are among big pharma's best-selling products
Apr 24 / FT.com - Paid Partner Content
Why I Think Pfizer Is a Better Buy Than Merck & Co.
May 12 / MotleyFool.com - Paid Partner Content